Bellevue Life Sciences Acquisition Corp. Share Price Nasdaq

Equities

BLACU

US0791742077

Investment Holding Companies

Market Closed - Nasdaq 21:30:00 05/06/2024 BST 5-day change 1st Jan Change
10.86 USD -.--% Intraday chart for Bellevue Life Sciences Acquisition Corp. -.--% +2.36%
Sales 2022 - Sales 2023 - Capitalization 95.08M 7.51B
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 * -
Net Debt 2022 1.09M 86.24M Net Debt 2023 56.58K 4.47M EV / Sales 2023 -
P/E ratio 2022 *
-
P/E ratio 2023
210 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 48.02%
More Fundamentals * Assessed data
Dynamic Chart
Bellevue Life Sciences Acquisition Corp. Announces Directorate Resignations CI
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.14 million in funding CI
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.05 million in funding CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $1.2 million in funding CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.06 million in funding CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.075 million in funding CI
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Certain Common Stock of Bellevue Life Sciences Acquisition Corp. are subject to a Lock-Up Agreement Ending on 9-AUG-2023. CI
Bellevue Life Sciences Acquisition Plans to Take OSR Holdings Public in SPAC Merger Deal MT
OSR Holdings.Co.,Ltd. entered into an exclusive, non-binding letter of intent to acquire Bellevue Life Sciences Acquisition Corp. in a reverse merger transaction. CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.2 million in funding CI
Bellevue Life Sciences Acquisition Corp. Announces the Resignation of Hosun Euh as Member of the Board of Directors, Effective June 21, 2023 CI
More news
1 month-1.63%
3 months-3.77%
6 months+2.36%
Current year+2.36%
More quotes
1 month
10.86
Extreme 10.86
11.10
Current year
10.65
Extreme 10.65
11.47
1 year
10.09
Extreme 10.085
11.47
3 years
10.09
Extreme 10.085
11.47
5 years
10.09
Extreme 10.085
11.47
10 years
10.09
Extreme 10.085
11.47
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 29/02/20
Director of Finance/CFO 50 31/08/21
Members of the board TitleAgeSince
Chief Executive Officer 48 29/02/20
Director/Board Member 59 31/07/20
Director/Board Member 56 13/02/23
More insiders
Bellevue Life Sciences Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company has not selected any business combination target, and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company may pursue an acquisition opportunity in any business industry or sector. The Company intends to acquire and manage a business in the healthcare industry, more specifically in the biotechnology sector. The Company neither engaged in any operations nor generated any revenues.
More about the company